Mizuho Securities analyst Salim Syed maintained a Buy rating on Assembly Biosciences (ASMB) today and set a price target of $13.00. The company’s shares closed last Thursday at $5.94, close to its 52-week low of $4.78.
According to TipRanks.com, Syed has 0 stars on 0-5 stars ranking scale with an average return of -5.7% and a 46.2% success rate. Syed covers the Healthcare sector, focusing on stocks such as Atara Biotherapeutics, Coherus Biosciences, and Wave Life Sciences.
Assembly Biosciences has an analyst consensus of Moderate Buy, with a price target consensus of $11.50.
See today’s analyst top recommended stocks >>
The company has a one-year high of $27.84 and a one-year low of $4.78. Currently, Assembly Biosciences has an average volume of 1.06M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Assembly Biosciences, Inc. is a biotechnology company, which engages in the development of products for infectious diseases, such as chronic hepatitis B virus and illnesses associated with a dysbiotic microbiome. It focuses in two innovative platform programs: oral therapeutics for the treatment of hepatitis B virus, and the oral synthetic live biotherapeutics candidate. The company was founded by Uri Lopatin on October 7, 2005 and is headquartered in Carmel, IN.